Generic drugs approved by FDA (through July 2010): Naratriptan hydrochloride tablets, Famotidine for oral suspension, Adapalene cream, Enoxaparin sodium injection, Oxymorphone hydrochloride
Naratriptan hydrochloride tablets in the 2.5-mg strength (equiv to Amerge)
SANDOZ
Famotidine for oral suspension, 40 mg/5 mL (equiv to Pepcid)
LUPIN
Adapalene cream in the 0.1% strength (equiv to Differin)
FOUGERA AND GLENMARK
Oxymorphone hydrochloride (equiv to Opana) extended-release 30-mg tablet in 5-mg, 10-mg, 20-mg, and 40-mg tablets.
IMPAX LABORATORIES
Get the latest industry news, event updates, and more from Managed healthcare Executive.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Expands Kerendia’s Use to Treat Common Form of Heart Failure
July 14th 2025Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic kidney disease (CKD) associated with type 2 diabetes. This new approval extends its use to a broader patient population.
Read More